• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Uroplasty wins Medicare coverage for neuromodulation device

Uroplasty wins Medicare coverage for neuromodulation device

November 29, 2012 By MassDevice staff

Uroplasty logo

Uroplasty (NSDQ:UPI) landed a couple of regional Medicare coverage wins for posterior tibial nerve stimulation treatment of overactive bladder using the company’s neuromodulation device.

Health Net from California and Minnesota-based Medica granted Medicare reimbursement for the procedure, effective October 2012. Health First of Florida also acknowledged coverage for approximately 120,000 regional beneficiaries, according to a press release.

"This expanded coverage demonstrates that more payers understand the role of PTNS in treating OAB. The additional coverage provides physicians and over 4.3 million newly covered patients another treatment option for OAB, " president & CEO David Kaysen said in prepared remarks. "As payers and providers recognize that PTNS is a viable OAB treatment option, the paradigm of care for this often debilitating condition is changing dramatically."

Health Net is the one of the largest private insurance payers in California, with about 2.5 million customers primarily in California, Arizona and Oregon, and Medica added coverage for approximately 1.7 million beneficiaries in Minnesota, North Dakota, South Dakota and Wisconsin, according to a press release.

Uroplasty in October presented 3-year PTNS data at the Western Section of the American Urological Assn. in Waikoloa, HI, showing sustained therapeutic effects from continued PTNS treatments. Medicare administrators Noridian Administrative Services, Palmetto GBA J1 and J11 expanded PTNS coverage from 1 to 2 years based on that data, Uroplasty said

Minnetonka, Minn.-based Uroplasty in 2010 won additional Medicare coverage for its neuromodulation device from some regional Medicare carriers and notched another reimbursement win in 2011 from 2 private payers, representing 13.7 million new patients covered by UrgentPC non-invasive overactive bladder nerve stimulation treatment.

Filed Under: Medicare, Neuromodulation/Neurostimulation, News Well Tagged With: Minnesota, Uroplasty Inc.

More recent news

  • EBR Systems raises $36.1M for leadless pacing tech
  • The biggest cardiovascular tech news out of EuroPCR 2025
  • CardiaWave has positive 12-month Valvosoft results
  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Medtronic has new Cardiovascular, CST leaders after longtime exec departs

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy